Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy.

摘要: Pharmacogenomics is defined as research into inherited genetic variations that determine an individual's response to therapeutic agents. In oncology, pharmacogenomics based on somatic molecular alterations by subsequent cancer cell generations forms the basis of targeting novel What has emerged from clinical experience with such agents need for appropriate pharmacodiagnostic approaches ensure drugs are correctly targeted. Given broad range pharmacogenomic currently under evaluation therapy, it appears a rapid extension profiling will be required in next 5-10 years, if not sooner. If this successfully achieved, lessons learned past, particularly during development HER2 (ERBB2) testing directing trastuzumab therapy breast cancer, may provide valuable framework future assays system. This article reviews biological and rationale steps taken validate improve procedures tumor protein expression gene amplification. Attention given quality assurance reproducibility optimal selection patients trastuzumab. approach serves paradigm tests oncology.